Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Vical will stay alive through a reverse merger with privately held Brickell Biotech, which develops dermatology treatments. The combined company will have roughly $35 million in cash to support late-stage clinical studies of sofpironium bromide, Brickell’s anticholinergic for a form of excess sweating called axillary hyperhidrosis. In February, Vical laid off staff and said it was considering its options after ending development of its lead drug candidate, VL-2397.
This article has been sent to the following recipient: